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Abstract: Dengue viruses (DENV) are the causative agents of dengue fever (DF) and 
dengue hemorrhagic fever (DHF). Here we review the current state of knowledge about the 
human antibody response to dengue and identify important knowledge gaps. A large body 
of work has demonstrated that antibodies can neutralize or enhance DENV infection. 
Investigators have mainly used mouse monoclonal antibodies (MAbs) to study interactions 
between DENV and antibodies. These studies indicate that antibody neutralization of 
DENVs is a “multi-hit” phenomenon that requires the binding of multiple antibodies to 
neutralize a virion. The most potently neutralizing mouse MAbs bind to surface exposed 
epitopes on domain III of the dengue envelope (E) protein. One challenge facing the 
dengue field now is to extend these studies with mouse MAbs to better understand the 
human antibody response. The human antibody response is complex as it involves a 
polyclonal response to primary and secondary infections with 4 different DENV serotypes. 
Here we review studies conducted with immune sera and MAbs isolated from people 
exposed to dengue infections. Most dengue-specific antibodies in human immune sera are 
weakly neutralizing and bind to multiple DENV serotypes. The human antibodies that 
potently and type specifically neutralize DENV represent a small fraction of the total 
DENV-specific antibody response. Moreover, these neutralizing antibodies appear to bind 
to novel epitopes including complex, quaternary epitopes that are only preserved on the 
intact virion. These studies establish that human and mouse antibodies recognize distinct 
epitopes on the dengue virion. The leading theory proposed to explain the increased risk of 
severe disease in secondary cases is antibody dependent enhancement (ADE), which 
postulates that weakly neutralizing antibodies from the first infection bind to the second 
serotype and enhance infection of FcγR bearing myeloid cells such as monocytes and 




macrophages. Here we review results from human, animal and cell culture studies relevant 
to the ADE hypothesis. By understanding how human antibodies neutralize or enhance 
DENV, it will be possible to better evaluate existing vaccines and develop the next 
generation of novel vaccines. 
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1. Introduction 
Dengue viruses (DENV) are emerging, mosquito-borne flaviviruses and are the causative agents of 
dengue fever (DF) and dengue hemorrhagic fever (DHF). Millions of people living in tropical and 
subtropical regions of the world are infected by DENV each year. Several hundred thousand of these 
infections progress to DHF, which is a life threatening disease [1]. The DENV complex consists of  
4 distinct but related viruses designated as serotypes. DENVs display antibody epitopes that are unique 
to each serotype and epitopes that are shared between serotypes. People who have recovered from 
primary DENV infections develop robust antibody responses that cross react with the 4 serotypes. 
Despite the cross reactivity, antibodies only prevent re-infection by the same serotype (homologous 
serotype) and individuals are susceptible to a second infection with a different serotype (heterologous 
serotype) [2,3]. People experiencing a secondary dengue infection with a new serotype face a much 
greater risk of developing DHF indicating that pre-existing immunity to DENV can exacerbate disease. 
Antibody dependent enhancement (ADE) of DENV is the most widely supported theory explaining the 
higher risk of DHF associated with secondary infection [4]. Thus, the antibody response to DENV 
infection is complex, with potential to benefit or harm the host. Currently many dengue vaccines are 
under development including live attenuated DENV vaccines, which are entering phase III human 
trials. An in-depth understanding of the human antibody response to DENV is highly relevant to 
evaluating vaccines already in the pipeline and for developing new vaccines. Here we review the 
current state of knowledge about the human antibody response to DENV infection and identify 
important gaps in our knowledge. 
2. Dengue Virion Structure 
The structural arrangement of viral surface proteins plays an important role in dictating how 
antibodies neutralize viruses. Dengue is an enveloped, positive-strand RNA virus that produces a 
spherical particle with a diameter of approximately 500A. The viral envelope contains two integral 
membrane proteins designated envelope (E) and pre membrane (prM). E protein binds to cellular 
receptors and mediates fusion of viral and cellular membranes during viral entry into cells. E protein is 
also the main target of neutralizing antibodies. The crystal structures of the E protein of several 
flaviviruses have been solved [5–10]. Individual subunits of E protein consist of three beta-barrel 
domains designated domains I (EDI), II (EDII) and III (EDIII), with the native protein forming a  
head-to-tail homodimer (Figure 1). The hydrophobic viral fusion peptide is located at the tip of domain 




binding to cellular receptors as several mutations that affect receptor binding are located in this 
domain [2]. A detailed picture of how E protein dimers are organized on the surface of the mature, 
infectious virion has been obtained by combining the crystal structures of E with cryo-EM 
reconstructions of the entire virion [11] (Figure 1). Each virus particle has 180 monomers of E that are 
organized into 90 tightly packed dimers that lie flat on the surface of the viral membrane (Figure 1B). 
Another important feature is that individual E subunits are organized in 2, 3 and 5 fold axes of the T-3 
icosahedral structure of the virion. Thus, all the E protein subunits are not in identical environments on 
the viral surface and steric and other considerations will result in preferential interactions of some E 
subunits over others with receptors and antibodies [11–13]. 
Figure 1. Structure of dengue virus envelope protein (A) and the dengue virus particle (B). 
(A) E protein on the mature virion is a homodimer and each subunit has three domains 
designated I (red), II (yellow) and III (blue). (B) Arrangement of E proteins on the surface 
of the virion. Both images A and B are from [12]. 
 
 
Dengue virions are assembled on the membrane of the endoplasmic reticulum (ER) and the virus 
buds into the lumen of the ER as immature virions. Unlike mature virions that have a smooth surface, 
immature virions that bud into the ER have a rough surface created by trimers of E/prM heterodimers 
that form spikes on the viral envelope (reviewed in [14]) (Figure 2). These immature particles 
transition to mature particles during secretion out of infected cells. In the trans-Golgi compartment a 
cellular protease cleaves prM protein to generate the mature M protein, which also results in the 




the smooth surface observed in mature, infectious virions (reviewed in [14]) (Figure 2). In practice the 
process of intracellular DENV maturation appears to be inefficient because many immature and 
partially mature virions are also released from infected cells [15,16]. Moreover, recent studies indicate 
that partially mature and even fully immature particles can be infectious under some conditions 
[17,18]. The structural and maturation properties of DENVs must be considered when defining 
epitopes engaged by human antibodies and the functional consequences of antibodies binding. 
Figure 2. Maturation of dengue virions. Dengue virions bud into the endoplasmic 
reticulum as immature, non-infectious particles. The surface of immature particles has a 
jagged appearance because prM and E proteins are initially assembled as trimeric spikes 
that protrude away from the envelope. In the trans-Golgi compartment a cellular protease 
cleaves prM protein to generate the mature M protein, which also results in the 
rearrangement of E protein trimers to form dimers that lie flat on the surface of the 
envelope creating the smooth surface observed in mature, infectious virions released into 
the extracellular space. The images reproduced here are from [19]. 
 
3. Studies with Mouse MAbs and the Multi-Hit, Threshold Model of Dengue Neutralization 
Most studies to understand how antibodies neutralize or enhance DENV have been done with 
mouse monoclonal antibodies (MAbs) (reviewed in [20,21]). As E protein is the main antigen exposed 
on the surface of the virion, mouse MAbs that bind to E protein have been the focus of much study. 
Although neutralizing mouse MAbs have been mapped to all three domains, the most strongly 
neutralizing MAbs are serotype-specific and bind to domain III of E protein (EDIII), which protrudes 
from the surface of the virion (Figure 3). Two partially overlapping epitopes on EDIII designated the 
lateral ridge and A strand epitopes are the main targets of mouse MAbs that neutralize DENV. The 




that bind to the A strand epitope cross react with more than one serotype of DENV and are designated 
dengue sub complex neutralizing MAbs.  
Figure 3. Location of mouse MAb epitopes on DENV E protein. The figure is based on the 
structure of the ectodomain of DENV3 E protein solved by Modis and colleagues [7]. 
(A) The image depicts the major regions on domains I (red) and II (yellow) recognized by 
mouse MAbs. (B) An enlarged view of domain III (blue) displaying the lateral ridge and A 
strand epitopes recognized by strongly neutralizing mouse MAbs. Figure originally 
published in [22]. 
 
 
Mouse antibodies have also been used to explore mechanisms of dengue neutralization. There are 
180 potential binding sites on the virion for an antibody that binds to E protein. However, as indicated 
above all 180 molecules are unlikely to be bound by antibody because of steric effects and limited 
accessibility of some epitopes. For example, as several EDIIIs are closely packed around the axis of  
5 fold symmetry (Figure 1), an antibody binding to one EDIII will obstruct antibody binding to 
adjacent EDIIIs. It is also becoming clear that the hypothetical structure of the mature flavivirus 
particle generated by cryo-EM and molecular fitting does not always predict epitope exposure. Binding 
of some E reactive antibodies depends on the dynamic movement of protein molecules (“breathing”) in 
the virion particle leading to transient exposure of hidden epitopes. For instance, optimal binding of 
mouse MAb 1A1D2 to EDIII requires incubation at 37 °C [23]. The structure of the 1A1D2 bound to 
EDIII indicates that the antibody binds to sites that are transiently exposed during viral “breathing” 




There are at least two if not more distinct mechanisms by which mouse MAbs neutralize DENV in 
cell culture. Some antibodies neutralize by blocking attachment of the virus to cells, whereas others 
neutralize by blocking a post attachment step in the entry process (reviewed in [21]). Antibodies that 
neutralize at a post-attachment step presumably block viral fusion with cellular membranes. Low pH 
triggered flavivirus fusion requires large conformational changes of E protein molecules and 
antibodies may interfere with this process required for entry [24,25]. Flavivirus neutralization requires 
the binding of multiple antibodies (reviewed in [21]). Studies with E16, an EDIII binding MAb that 
potently neutralizes West Nile virus at a post attachment stage, indicate that ~30 antibodies need to 
bind for effective neutralization. Based on this and other studies, Pierson and colleagues have proposed 
that flaviviruses are only neutralized after the number of antibodies bound to the virion exceeds a 
critical threshold. Important implications of the threshold model are that both the affinity of antibody 
binding and the total number of accessible epitopes contribute to the neutralization potency of an 
antibody. Thus, even for an antibody that binds with high affinity, the antibody will fail to neutralize if 
the number of accessible epitopes is below the threshold required for neutralization. Conversely, a 
lower affinity antibody may neutralize if many of the epitopes are accessible to binding. The most 
potently neutralizing antibodies would be those that bind with high affinity to epitopes that are exposed 
and present in large numbers on the surface of the virion.  
It is unclear if the E16 results can be broadly generalized to most antibodies that neutralize 
flaviviruses. In other words, is the threshold of 30 true for most if not all flavivirus binding antibodies? 
Alternatively, does the threshold change depending on the location of binding? Does the threshold 
model hold for both pre and post attachment neutralizing MAbs? Do the rules depend on the cell type 
that is being infected as well as the entry receptors and Fc receptors being expressed by the cell? 
Finally and most importantly, can the threshold model apply to virus neutralization in immune sera 
when multiple antibodies that bind to different epitopes come into contact with the virion?  
4. Human Antibody Response Following Natural DENV Infection  
People exposed to DENV infections have detectable specific antibody for decades if not longer. A 
large fraction of the response cross reacts with all 4 serotypes and even other flaviviruses. In fact the 
dominance of cross reactive antibodies precludes the use of simple antigen binding assays to identify a 
flavivirus responsible for infection. The functional, neutralizing antibody response is more specific and 
useful for identifying the flavivirus responsible for infection. Early studies on the durability of the 
immune response following DENV infection were conducted by Sabin (1952). Sabin infected naive 
volunteers with DENV2 (NGC) and DENV 1(Hawaii) and re-challenged these individuals with the 
homologous virus at different times after the first infection. The subjects were protected up to 18 
months (last time point of the study) from re-infection with the same serotype. However, when 
challenged with a heterologous serotype, cross protection only lasted for 2–3 months after the first 
infection. Heterologous infection not only produced clinical signs of the disease but also produced 
sufficient viremia for mosquitoes to acquire infection. Sabin’s work demonstrated that protection was 
long term against the homologous serotype and only transient against a heterologous serotype. These 
observations are in agreement with natural history studies of dengue in endemic countries that indicate 




term protective response that is specific just to the infecting serotype. A recent study by Chan and 
colleagues provide a molecular basis for this initial broad cross neutralizing response [26]. These 
investigators demonstrated that early convalescent sera contain high concentrations of weakly 
neutralizing, cross reactive antibodies capable of forming large virus-antibody aggregates, which then 
bound to inhibitory FcγRIIB receptors on the surface of monocytes. The protection afforded by this 
class of antibody is likely to be transient because levels of cross reactive antibodies decline over time. 
In contrast, potently neutralizing, type-specific antibodies did not require the formation of aggregates 
for effective neutralization [26]. Type specific neutralizing antibodies can be detected even 60 years 
after a primary infection [27].  
Several months after a primary dengue infection, individuals are susceptible to a secondary 
infection with a new serotype. A hallmark of secondary dengue is a more rapid and elevated antibody 
response compared to the primary response. The rapid and elevated response is caused by the 
stimulation of memory B-cells from the primary infection. The first antibodies that appear following a 
secondary infection neutralize the serotype responsible for the primary infection better than the second 
virus [28,29]. This phenomenon has been termed “original antigenic sin”, although the molecular basis 
and mechanisms responsible are incompletely understood [30,31]. Over time, the neutralizing antibody 
response broadens and a key feature of secondary dengue is a long-lasting response that neutralizes 
multiple serotypes including serotypes that have not previously infected the individual. Tertiary DENV 
infections have been documented only rarely, further supporting the notion that secondary infections 
stimulate long term cross neutralizing antibody that may even be effective against serotypes not 
encountered previously [32,33].  
Investigators have also characterized the kinetics and isotypes of the DENV-specific serum 
antibody response in infected people. Following a primary DENV infection, DENV-specific IgM 
antibodies appear 4–5 days after onset of fever and are measurable for up to 3 months. IgG antibodies 
first appear about a week after onset of fever. The IgG response peaks several weeks after infection 
and then declines to lower levels that persist for decades if not longer. DENV infection mainly induces 
IgG1 and IgG3 subclasses of antibody indicating a Th1 biased immune response [34–37]. WNV 
infection also induces a strong IgG1 response that is protective both in cell culture and in animals [38]. 
The serum antibody responses are different following primary and secondary DENV infections. 
Antibodies produced during a second infection arise from naïve B-cells and memory B-cells generated 
from the primary infection. In secondary infections, the stimulation of B-cell memory leads to a rapid 
rise in DENV-specific IgG that is measurable even on the first day of symptoms. Moreover 
DENV-specific serum IgG titers are much higher in secondary compared to primary infections. For 
reasons that are not completely understood, in secondary dengue the IgM response is variable, and 
some cases undetectable.  
5. DENV Antigens and Epitopes Recognized by Human Antibodies 
In comparison to the work done with mouse MAbs, we are just beginning to learn about the main 
antigens and epitopes on the dengue virion targeted by human antibodies. Studies have been done with 
dengue immune sera and human MAbs to define the specificity of the human response. We will start 




DENV infection, people develop serum antibodies against the structural proteins (E,PrM, C) as well as 
some of the non-structural proteins (NS1,NS3,NS5) [39–44]. Some investigators have reported on 
higher levels of prM and NS1 antibodies in secondary compared to primary infections [39–41]. 
However, it is unclear if this is due to the overall high levels of antibody in secondary infections or if 
the antibody responses to prM and NS1 are specifically elevated in secondary infections. Antibodies 
that bind to NS1 are particularly interesting as this is a non-structural protein that is secreted from 
infected cells. In one mouse model of lethal dengue infection, NS1 antibodies were protective [45]. It 
has also been reported NS1 antibodies cross react with self-antigens on platelets and endothelial cells, 
and investigators have proposed this as a possible mechanism of damage to the vasculature in severe 
dengue (reviewed in [46]). Although antibodies against NS3 and NS5 have been detected in people, 
these antibodies are unlikely to influence infection or disease because NS3 and NS5 are intracellular 
antigens that would not encounter antibody.  
Serum antibodies against DENV E protein have been the focus of several studies as this is the main 
antigen on the virion surface and the target of neutralizing antibody [39,40,42–44,47]. Mutations in the 
conserved fusion loop on domain II of E protein reduced the binding of immune sera substantially 
indicating the fusion loop region is a major target of the human antibody response [41]. However, 
fusion loop antibodies are unlikely to be the target of serotype-specific, potently neutralizing antibody 
because the fusion loop is well conserved between serotypes. Following up on mouse MAb studies, 
investigators have tested if EDIII epitopes are the main target of neutralizing antibodies in human 
immune sera as well. EDIII antibodies are present at low levels in human immune sera and Crill and 
co-workers observed a correlation between levels of EDIII antibody and neutralization potency of 
immune serum samples [48]. However, Wahala and Midgely, who used recombinant EDIII protein to 
deplete sera of EDIII binding antibody observed only a small effect on neutralization following the 
removal of EDIII binding antibodies [29,49]. Studies with immune sera from horses and people 
exposed to West Nile virus have also demonstrated that neutralizing antibodies generated following 
natural infection are not mainly directed to epitopes on EDIII [50,51]. Thus, the main epitopes on 
DENV targeted by neutralizing antibodies in immune sera remain to be defined.  
6. Profiling Antibody Response to Dengue Virus Using Human Monoclonal Antibodies 
Several groups have generated panels of dengue reactive human monoclonal antibodies (hMAbs) 
[17,52–54]. The hMAbs were generated by using the method of EBV transformation of memory 
B-cells from dengue immune subjects [55]. While it had previously been assumed that E protein was 
the main target of antibody, the hMAbs indicate a more complex picture. Both E and prM were 
common targets of human antibody [17,52]. A particularly interesting class of hMAbs, were those that 
bound to the intact virion but not individual subunits of E or prM [17,52]. The latter class indicates that 
some B-cell epitopes are only expressed when the viral proteins are assembled to form virions. Studies 
with dengue immune sera also indicate that only 5–35% of serum antibodies bind to the ectodomain of 
E expressed as a recombinant antigen, indicating that a substantial fraction of antibodies bind to prM 
and/or E epitopes that are only expressed on the virion [52]. 
Functionally, the majority of human MAbs produced have been weakly neutralizing and serotype 




circulation is also cross reactive, and weakly neutralizing [17,52,53]. Potently neutralizing hMabs are 
rare indicating that only small fraction of the total antibody response is responsible for virus 
neutralization. The neutralizing hMAbs include (1) antibodies that bind to the virion but not 
recombinant E protein, (2) antibodies that bind to EDI/II, and (3) antibodies that bind to lateral ridge 
and A strand epitopes on EDIII (see Figure 3) [52]. These results demonstrate that human neutralizing 
antibodies bind to well defined epitopes on EDIII as well as novel epitopes on EDI/II and epitopes 
preserved only on the intact virion. Non-human primates also develop potently neutralizing antibodies 
that bind to novel epitopes. Chimpanzee MAb 5H2 is a potently neutralizing, type-specific antibody 
that has been mapped to EDI [56]. Of particular interest are studies conducted by Diamond and 
colleagues with hMAbs generated from people who have recovered from West Nile virus infection 
[57,58]. Two strongly neutralizing hMAbs bound to the West Nile virion but not recombinant E 
protein [57,58]. The structure of one of the antibodies (CR4354) bound to the West Nile virion 
demonstrated that the antibody bound to a complex epitope that spanned EDI/II and EDIII from 
adjacent dimers (Figure 4), which was consistent with the observation that this class of antibody bound 
to the virion but not recombinant E protein [57]. These antibodies appear to block infection by cross 
linking E proteins on the virion and blocking conformational changes required for viral entry and 
fusion [57]. In summary, these results demonstrate that human antibodies that potently and type 
specifically neutralize DENV represent a small fraction of the total DENV-specific antibody response. 
Moreover, these neutralizing antibodies appear to bind to novel epitopes including complex, 
quaternary epitopes that are only preserved on the intact virion. 
Figure 4. Quaternary structure epitope recognized by West Nile human MAb CR4354. The 
figure depicts a raft of three E protein homo dimers, which is the basic building block of 
the flavivirus envelope. The domains of E protein are color coded as described in figure 1. 
The approximate footprint of human MAb CR4354 is circled. Note that the foot print 
encompasses EDI/II and EDIII from adjacent dimers. One hundred and twenty CR4354 
epitopes are predicted to be available on a virion for antibody binding. Figure adapted 
from [57,59].  




PrM Protein Is a Major Target of the Human Antibody Response  
A surprisingly high proportion of hMAbs bound to prM, which is an antigen that has not received 
much attention as an antibody target [17,52,53]. prM antibodies cross reacted with all 4 serotypes and 
their neutralization capacity ranged from poor to moderate at best. PrM reactive antibodies enhanced 
DENV infection in FcγR bearing cells in vitro, over a large range of antibody concentration [17,53], 
indicating their potential involvement in antibody dependent enhancement (ADE) of dengue, which is 
discussed later in this review.  
7. Intra-Serotype Strain Variation and DENV Neutralization 
DENVs within each serotype are genetically diverse and classified into distinct genotypes with 
different geographical distributions and pathogenic potential (reviewed in [60,61]). Despite this genetic 
variability, it is widely assumed that neutralizing antibody epitopes are conserved among strains 
belonging to the same serotype. In fact, the current strategy for developing dengue vaccines is based 
on the assumption that a neutralizing immune response directed to a single strain will protect against 
most if not all strains of DENV within the serotype. The idea that strain variation within a serotype 
does not affect neutralization is mainly based on the observation that in human cohort studies one 
rarely, if ever, observes re-infection with the same serotype. We argue that this observation alone does 
not mean intra-serotype strain variation is irrelevant for neutralization because most cohort studies 
have been done in areas where each serotype is represented by the circulating of a single genotype. We 
need prospective studies that specifically assess what happens when a new genotype is introduced into 
a population with pre-existing immunity to the serotype. Several recent, laboratory based studied 
indicate that intra-serotype variation can lead to large differences in antibody neutralization. Blaney 
and colleagues immunized monkeys with candidate live attenuated dengue vaccines and characterized 
the immune response in monkeys by using a panel of viruses representing the 4 serotypes and 
genotypes within each serotype. They observed large differences in neutralization titer when 
comparing different genotypes of DENV3 [62]. In a study of pediatric dengue cases in Thailand, 
investigators observed significant differences in the ability of sera to neutralize reference and clinical 
strains of DENV3 [63]. Guzman and colleagues reported that amino acid sequence differences 
between DENV3 strains can have strong influences on virus neutralization by murine and human 
immune sera [64]. Studies with other flaviviruses have also demonstrated that neutralization is 
dependent on the lineages and strains used in the assay [65,66]. A series of studies from our group and 
the Diamond group recently demonstrated that the ability of many monoclonal antibodies to neutralize 
DENV1, 2 and 3 was dependent on the genotype used in the neutralization test [22,67–69]. These 
studies have also led to the identification of point mutations that profoundly alter the neutralization 
titer. More recently, we have observed a 4 to 10 fold difference in the neutralization titer of human 
immune sera when recombinant viruses with prM and E from different DENV3 genotypes were used 
in the neutralization test [70]. Thus, the current paradigm that neutralizing antibody epitopes are 
conserved within each serotype needs to be tested more vigorously both in the field and in the laboratory.  




8. In Vitro versus in Vivo Neutralization 
Studies are needed to assess the relationship between cell culture antibody neutralization of DENVs 
and in vivo protection from infection and disease. Typically cell culture neutralization is based on 
antibodies binding to the virion and directly interfering with infection. In vivo the situation is more 
complex and antibodies can interact with other components of the immune system such as complement 
and Fc receptors, which can augment or suppress virus neutralization [4,71–76]. Moreover, antibodies 
can also harness cellular mechanisms such as phagocytosis and antibody dependent cellular 
cytotoxicity (ADCC) to control DENV infection [77,78]. Despite these differences, some studies have 
reported on a strong correlation between in vitro neutralization potency and in vivo protection both 
with monoclonal antibodies and polyclonal sera [79]. A recent study of infants with maternally derived 
DENV- specific antibody indicated that an in-vitro neutralization titer of 1:50 is predictive of 
protection in vivo as well [80]. However, some flavivirus antibodies with poor naturalizing activity in 
cell culture can protect from disease in animal models [45,81,82]. Further studies are needed to define 
the main mechanisms by which antibodies protect people from severe dengue disease.  
9. B-Cell Subsets Involved in the Humoral Response to DENV 
As detailed above, most work to date on the human antibody response to DENV has focused on 
circulating serum antibody and MAb generated from the memory B-cell pool. Studies are needed to 
identify the actual B-cell subsets activated by dengue and to characterize the functional importance of 
antibody produced from different B-cell populations. Most antibodies stimulated by viruses are 
classical T-dependent responses derived from follicular B-cells. The main antibody response to DENV 
is also likely to involve T-dependent follicular (B-2) B-cells, which differentiate into long lived plasma 
cells and memory B-cells. Recent studies indicate that less well studied B-cell subsets such as marginal 
zone B-cells and B1a and B1b cells, which give rise to natural and T-independent antibody responses 
provide protection from viruses [83]. Studies are needed to assess if similar responses constitute 
important components of the response to DENV as well. In this regard the recent observation that 
many human flavivirus antibodies recognize epitopes preserved on the intact virion but not 
recombinant E protein is intriguing as such antibodies may be produced by the multivalent virus 
particle directly activating B-cells without any T-cell help [17,52,57]. DENV infection also inhibits 
type I interferon responses and suppresses antigen presentation by myeloid cells and these effects are 
likely to influence the quality of the adaptive immune response, including antibody production. We 
need to invest in human studies and animal models to characterize B-cell subsets involved in the 
response DENV, with particular attention to how these responses differ in primary versus secondary 
cases, or severe versus mild disease cases.  
10. Role of Antibodies in Enhancing DENV Infection and Disease 
Many studies in different regions of the world have documented that individuals exposed to 
secondary infections are at greater risk of developing severe disease compared to individuals exposed 
to primary infections (reviewed in [84]). The leading theory proposed to explain the increased risk of 




weakly neutralizing antibodies from the first infection bind to the second serotype and enhance 
infection of FcγR bearing myeloid cells such as monocytes and macrophages (reviewed in [4]). Here 
we will discuss evidence for ADE from human, animal and cell culture studies.  
The fact that secondary infections lead to a higher serum viremia and a greater risk of severe 
disease compared to primary infections strongly suggests that pre-existing immunity (not necessarily 
antibody) to DENV is a risk factor for severe dengue. The most compelling evidence for ADE has 
come from studies with infants, who have passively acquired antibodies to DENV from their mothers 
[85–87]. Soon after birth high levels of maternal antibodies appear to protect infants from dengue. 
Infants born to dengue immune mothers are at greatest risk of developing severe dengue between 6–12 
months after birth and this has been attributed to maternal antibody decaying to low, sub-neutralizing 
levels that enhance DENV. Studies with older children experiencing secondary infections also provide 
evidence in support of ADE and severe disease. In one study, the ability of immune sera collected just 
before a second infection to enhance DENV in cell culture was positively correlated with risk of severe 
disease [88]. However, not all human studies support the ADE theory of DHF/DSS. For instance, in 
their study with maternally transferred antibodies in infants, Libraty et al. [80] did not find a 
significant association of ADE with the disease outcome. In a prospective study with school children 
in Thailand, ADE activity of pre-illness undiluted sera did not correlate with the severe disease 
severity or viral load following secondary infections [89]. While it is difficult to directly compare 
different studies because of differences in study design and methods, the ADE hypothesis is 
biologically plausible and supported by sufficient evidence to justify conducting more human cohort 
studies specifically designed to test the ADE hypothesis. 
It has proven challenging to test the ADE hypothesis in animal models because DENV replicates 
poorly in animals, and DHF and DSS are difficult to reproduce in animals models. Nonetheless a few 
studies indicate that antibody enhanced infection and severe disease can be reproduced in some 
animals. Studies with non-human primates [90,91] have demonstrated that animals treated with 
sub-neutralizing levels of antibody develop higher serum viremia compared to untreated animals. 
However, attempts to reproduce DHF in non-human primates have been unsuccessful. Investigators 
have attempted with some success to develop mouse models of DENV infection and disease (reviewed 
in [92]). The most successful mouse model of antibody enhanced severe disease is based on infecting 
interferon receptor-deficient AG129 mice with a mouse adapted strain of DENV2 [93,94]. AG129 
mice treated with anti-dengue monoclonal antibodies or polyclonal sera and then infected with DENV 
developed a lethal vascular leak disease, with similarities to DHF. The cells involved with ADE driven 
infection were Fc receptor bearing cells including sinusoidal endothelial cells in the liver. In addition 
to vascular leakage, the disease was characterized by elevated level of cytokines (TNFα, IL-6, and 
IL-10), and thrombocytopenia, which is similar to severe DENV illness in humans [93,94]. While 
specific cellular mechanisms leading to vascular leakage are likely to be different in humans and mice, 
especially mice deficient in interferon receptors, these animal studies establish that antibodies can 
enhance viral replication and induce host cytokines responses that lead to clinical outcomes similar to 
DHF/DSS. Further development of appropriate animal models, including mice reconstituted with 
human immune cells, is an ongoing and exciting area of dengue research. 
The ADE phenomenon can be reproduced in cell culture models. Fcγ receptor bearing human cell 




become highly permissive to infection in the presence of sub-neutralizing antibody concentrations. 
ADE has been well demonstrated with monoclonal antibodies and polyclonal sera in vitro using Fcγ 
receptor bearing human cells such as K562, U937, and primary human monocytes, macrophages and 
dendritic cells. Initially it was believed that ADE simply resulted from a greater number of infected 
cells producing more infectious virions (extrinsic ADE). However, recent studies by Ubol and 
colleagues with THP-1 cells (a human acute monocytic  leukemia  cell line) indicate that the 
phenomenon is more complex [95]. DENVs entering THP-1 cells via Fc receptors suppressed type I 
interferon responses and the activation of cellular antiviral molecules more effectively than DENV 
infecting the same cells in the absence of antibody [95–97]. Moreover, THP1 cells infected in the 
presence of antibody produced more infectious virus per infected cell compared to cells infected in the 
absence of antibody. This phenomenon, which has been termed “intrinsic ADE” demonstrates that 
antibody mediated infection leads to a suppression of the antiviral state within the infected cell and the 
release of a greater quantity of infectious virions by each infected cell compared to cells infected by 
antibody-independent entry. Ubol’s observations about intrinsic ADE have been confirmed by other 
groups working with primary human cells, although the specific mechanisms and molecules implicated 
appear to depend on the cell type being used or other variables introduced by the different laboratories 
performing these studies [98–100]. With THP-1 cells, antibody dependent infections inhibited type I 
interferon responses and increased levels of the suppressive cytokine IL-10 [97]. In studies with 
primary human PBMCs, one group did not observe any differences in type Type I IFN or IL-10 
levels [99] whereas another group observed decreased levels of type I interferon and increased levels 
of IL-6 [100]. Boonak and colleagues compared ADE infections in monocytes, macrophages and 
dendritic cells and observed increased IL10 production in primary monocytes but not in macrophage or 
dendritic cells [98]. The picture emerging from these studies is that antibody-complexed dengue 
viruses infecting cells via Fcγ receptors leads to the suppression of cellular antiviral responses but 
further studies are needed to better define the cellular pathways and mechanisms that contribute to 
this phenotype. 
11. Properties of DENV Enhancing Antibodies 
It is well established that almost any dengue specific MAb used at sub-neutralizing concentrations 
can enhance infection of cultured cells expressing appropriate Fcγ receptors. Studies are needed to 
identify specific antibody sub-populations in dengue immune human sera that drive ADE in cell 
culture and animal models and, potentially, in people exposed to secondary infections. When designing 
these studies, it is important to keep in mind that during a secondary DENV infection, ADE is likely to 
occur at circulating antibody concentrations present during the acute phase of infection. A recent study 
demonstrated a quantitative difference in the ability of primary immune sera to enhance a homologous 
versus heterologous DENV serotype [29]. Sera had to be diluted to artificially low concentrations to 
enhance the homologous virus whereas a heterologous serotype was enhanced at high serum 
concentrations, likely to be encountered by a virus responsible for a secondary infection. The actual 
target(s) of antibodies in human immune sera that enhance DENV infection have not been identified. 
In this regard, the previously mentioned, predominance of prM hMabs has raised the intriguing 




produced in cell culture is a complex mix of immature, partially mature and fully mature virions and 
these preparations are efficiently enhanced in vitro and in mice by prM antibodies [101]. By 
identifying the main antibodies in immune sera with potential for enhancing dengue at physiological 
concentrations, it will be possible to design vaccines that neutralize without potential for enhancement. 
12. Summary 
Although much remains to be learned about DENV pathogenesis, antibodies have emerged as 
important host molecules that reduce or exacerbate disease severity. Mouse MAbs have taught us that 
DENV neutralization is a multi-hit phenomenon requiring the number of antibodies bound to the virus 
to exceed a critical threshold. More recently, several groups have started to dissect the polyclonal and 
monoclonal human antibody response to DENV. The human antibody response has features that are 
similar to and different from the mouse response. The most striking difference is that strongly 
neutralizing mouse antibodies target epitopes on EDIII, whereas potent human antibodies bind to 
different epitopes on the viral envelope. Recent studies also indicate that the prM antigen on the 
DENV envelope is an, hitherto, under-recognized target of the human antibody response, and a 
potential target of infection and disease enhancing antibody. The field will evolve rapidly as we learn 
more about the human B-cell response and we develop better animal models for dengue. Over the next 
few years we are likely to witness many more important discoveries about the interactions of human 
antibodies with DENV, which will lead to a better understanding of dengue pathogenesis and 
improved methods for evaluating and developing vaccines. 
Notes Added in Proof 
While this manuscript was being reviewed, Mathew and colleagues published a study characterizing 
human B-cell responses following primary and secondary dengue infection [102]. The investigators 
demonstrated that people exposed to dengue have B-cells secreting antibodies that bind to E and NS1 
proteins and peptides derived from preM protein. Following primary infection, the B-cells produced 
antibodies that mainly recognized E protein from the homologous serotype. Following secondary 
infection, the E antibodies were mainly serotype cross-reactive. Antibodies produced after secondary 
infections displayed avidity differences between serotypes. 
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